Laws and sections by number or title, due dates, pages, and updates.
The Employees State Insurance Corporation revokes the delisting of item number 2093 and reinstates it in DG-ESIC Rate Contract No. 162. The competent authority acts on clarification from DCGI and CDSCO to allow the continuing supply of the item. The reinstated item contains Metformin Hydrochloride IP 500 mg and Glimepiride IP 1 mg. M/s Hab Pharmaceuticals and Research Limited holds L1 preference, M/s Unicure India Limited holds L2 preference, and M/s Overseas Health Care Private Limited holds L3 preference for this item. Rate Contract No. 162 remains valid up to 07.04.2027. Medical directors, deans, medical superintendents, dispensary incharges, and state directors follow these instructions.
What you must do
Key dates
Who is affected
Ask about this circular
कर्मचारी राज्य बीमा निगम (श्रम एवं रोजगार मंत्रालय, भारत सरकार) EMPLOYEES' STATE INSURANCE CORPORATION (Ministry of Labour & Employment, Govt. of India)
मुख्यालय/HEADQUARTERS पंचदीप भवन, सी.आई.जी मार्ग, नई दिल्ली 110002 Panchdeep Bhawan, C.I.G. Marg, New Delhi-110002 www.esic.gov.in, 011-23604773, dmc-rc@esic.nic.in
U-25/12/Off_Patent/Deletion_RC_item/2025-MedV (E- 1217106)
Web upload 457
सेवा में, Director (Medical) Delhi/Director (Medical) Noida Deans- All PGIMSR's/Medical/Dental Colleges Medical Superintendents-All ESI Hospitals Dispensary Incharges- Delhi/NCR/States Directors ESI Schemes- All State
संशोधन सं / Corrigendum-13 in DG ESIC RC NO. 162
विषयः-डीजी-ईएसआईसी दर अनुबंध संख्या 162 के संबंध में शुद्धिपत्र.
Sub: Corrigendum in r/o DG-ESIC Rate Contract No. 162- reg.
संदर्भः 1.) U-25/12/RC/159TO163/2022-Med.V (E-117064)/162 dtd 08.04.2025 2.) U-25/12/Off_Patent/Deletion_RC_item/2025-MedV (E- 1217106)/158 dated 05.05.2025, (console no. 20896/2025 dated 06.05.2025).
महोदय/महोदया
Reference captioned subject and in continuation to ESIC Hqrs earlier instructions vide letter no. U-25/12/Off_Patent/Deletion_RC_item/2025-MedV (E- 1217106)/158 dated 05.05.2025 (console no. 20896/2025 dated 06.05.2025).
In this context, it is hereby informed that in the light of Clarification received from DCGI/CDSCO and for continuing supply, the Competent Authority has revoked the de-listing and reinstate item no. 2093 under DG ESIC RC No.162 (valid upto 07.04.2027), as details below:
| S. No. | Name of approved Pharmaceutical Firm | RC No. | Item No. | Item Description |
|---|---|---|---|---|
| 1. | a.) M/s Hab Pharmaceuticals & Research Ltd:- L1 Preference b.) M/s Unicure India Ltd:- L2 preference c.) M/s Overseas Health Care Private Limited:-L3 preference | 162 | 2093 | Metformin + Glimepiride Tab/Cap-Each Uncoated Tab/Cap to contain :Metformin Hydrochloride IP 500 mg (As a Sustained Release, Glimepiride IP 1mg |
This is for your information and necessary action.
This issues with the approval of Competent Authority.
भवदीय
Digitally signed by Sanjiv Kochhar Date: 12-09-2025 13:18:20 उप चिकित्सा आयुक्त (दर संविदा)
प्रतिलिपिः
U-25/12/Off_Patent/Deletion_RC_item/2025-MedV
1/2507661/2025
कर्मचारी राज्य बीमा निगम (श्रम एवं रोजगार मंत्रालय, भारत सरकार) EMPLOYEES' STATE INSURANCE CORPORATION (Ministry of Labour & Employment, Govt. of India)
मुख्यालय / HEADQUARTERS पंचदीप भवन, सी.आई.जी मार्ग, नई दिल्ली 110002 Panchdeep Bhawan, C.I.G. Marg, New Delhi-110002 www.esic.gov.in, 011-23604773, dmc-rc@esic.nic.in
U-25/12/Off_Patent/Deletion_RC_item/2025-MedV (E- 1217106) / Dated: 1158
सेवा में, Director (Medical) Delhi/Director (Medical) Noida Deans- All PGIMSR's/Medical/Dental Colleges Medical Superintendents-All ESI Hospitals Dispensary Incharges- Delhi/NCR/States Directors ESI Schemes- All State
संशोधन सं / Corrigendum-06 in DG ESIC RC NO. 162
विषय: Corrigendum in r/o DG-ESIC Rate Contract No. 162- reg.
संदर्भ: U-25/12/RC/159TO163/2022-Med.V (E-117064)/162 dtd 08.04.2025
Sir/Madam
Reference captioned subject, it is hereby informed that following below mention drugs/items have been deleted from the approved item list of DG-ESIC Central Rate Contract No.162 (valid from 08.04.2025 to 07.04.2027) :
A)
| S. No. | Name of approved Pharmaceutical Firm | Item No. | Item Description | Preference | Remarks |
|---|---|---|---|---|---|
| 1 | M/s Boehringer Ingelheim India Private Limited | 2094 | Empagliflozin Tab/Cap Each film coated tab/cap to contain : Empagliflozin 10 mg Brand Name-(Jardiance® 10 mg) | 1st Preference | Off-Patent |
| 2 | M/s Boehringer Ingelheim India Private Limited | 2231 | Empagliflozin + Linagliptin- Each Tab/Cap to contain: Empagliflozin 10 mg + Linagliptin 5 mg Brand Name- GLYXAMBI® 5/10 mg | 1st Preference | Off-Patent |
U-25/12/Off_Patent/Deletion_RC_item/2025-MedV
1/2507661/2025
Contd. to pre-page:-
B)
| S. No. | Name of approved Pharmaceutical Firm with preference | Item No. | Item Description | Remarks |
|---|---|---|---|---|
| 1 | a. M/s Hab Pharmaceuticals & Research Ltd:- L1 preference b. M/s Unicure India Ltd:- L2 preference c. M/s Overseas Health Care Private Limited:- L3 preference | 2093 | Metformin + Glimepiride Tab/Cap- Each Uncoated Tab/Cap to contain : Metformin Hydrochloride IP 500 mg (As a Sustained Release, Glimepiride IP 1mg. | Withdrawal/Cancellation of FDC Approval by CDSCO |
This is for your information and necessary action.
This issues with the approval of Competent Authority.
Yours Sincerely
Digitally signed by Sanjiv Kochhar Date: 05-05-2025 Deputy Medical Commissioner (RC)
Copy to:
